Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

URGN

UroGen Pharma Ltd

Jul 26 • 04:00PM ET

16.35

Dollar change -0.01
Percentage change -0.06	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: IWM IBB IWO VTWO IZRL SPDW IWC IWN ITEQ SBIO

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.39	Insider Own	9.50%	Shs Outstand	41.17M	Perf Week	3.55%
Market Cap	673.13M	Forward P/E	-	EPS next Y	-2.64	Insider Trans	-0.66%	Shs Float	37.26M	Perf Month	-4.83%
Income	-104.32M	PEG	-	EPS next Q	-0.83	Inst Own	76.91%	Short Float	15.76%	Perf Quarter	18.31%
Sales	84.30M	P/S	7.98	EPS this Y	3.21%	Inst Trans	-0.46%	Short Ratio	9.11	Perf Half Y	6.72%
Book/sh	-1.11	P/B	-	EPS next Y	23.22%	ROA	-66.54%	Short Interest	5.87M	Perf Year	81.47%
Cash/sh	4.00	P/C	4.08	EPS next 5Y	-	ROE	-	52W Range	8.69 - 24.13	Perf YTD	9.00%
Dividend Est.	-	P/FCF	-	EPS past 5Y	5.89%	ROI	-179.57%	52W High	-32.24%	Beta	1.13
Dividend TTM	-	Quick Ratio	7.20	Sales past 5Y	13144.25%	Gross Margin	89.53%	52W Low	88.15%	ATR (14)	0.97
Dividend Ex-Date	-	Current Ratio	7.47	EPS Y/Y TTM	29.75%	Oper. Margin	-82.12%	RSI (14)	50.91	Volatility	5.35% 5.20%
Employees	201	Debt/Eq	-	Sales Y/Y TTM	24.00%	Profit Margin	-123.74%	Recom	1.40	Target Price	43.88
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	25.47%	Payout	-	Rel Volume	0.49	Prev Close	16.36
Sales Surprise	-12.20%	EPS Surprise	-11.93%	Sales Q/Q	9.24%	Earnings	May 13 BMO	Avg Volume	644.64K	Price	16.35
SMA20	-0.78%	SMA50	7.31%	SMA200	11.28%	Trades		Volume	314,828	Change	-0.06%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-08-23	Downgrade	Jefferies	Buy → Hold	$35 → $10
Apr-27-22	Initiated	Berenberg	Buy	$20
Apr-16-20	Reiterated	H.C. Wainwright	Buy	$53 → $57
Apr-13-20	Reiterated	H.C. Wainwright	Buy	$75 → $53
Jan-09-20	Initiated	National Securities	Neutral	$37
May-30-19	Initiated	JP Morgan	Neutral
May-29-19	Initiated	Goldman	Neutral
Jan-29-19	Initiated	H.C. Wainwright	Buy	$82
Nov-08-18	Resumed	Jefferies	Buy
Apr-04-18	Upgrade	Raymond James	Mkt Perform → Outperform
Jan-02-18	Initiated	Ladenburg Thalmann	Buy	$50
Nov-15-17	Reiterated	Oppenheimer	Outperform	$32 → $51
Nov-15-17	Downgrade	Raymond James	Outperform → Mkt Perform

Show Previous Ratings

Jul-17-24 09:55AM	Wall Street Analysts See a 149.01% Upside in Urogen Pharma (URGN): Can the Stock Really Move This High? (Zacks)
Jun-27-24 01:54PM	UroGen Pharma Stock Earns 91 RS Rating (Investor's Business Daily)
Jun-17-24 10:51PM	UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants (Business Wire) -7.71%
04:46PM	UroGen Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants (GlobeNewswire)
05:00AM	Urogen Pharma (URGN) Surges 9.7%: Is This an Indication of Further Gains? (Zacks)
04:05PM	Loading…
Jun-13-24 04:05PM	UroGen Catapults On 'Unprecedented' Results For Gel-Based Cancer Drug (Investor's Business Daily) +37.58% +9.71%
10:45AM	UroGen Announces Unprecedented 82.3% Duration of Response at 12 Months in the ENVISION Trial Investigating UGN-102 as Potentially the First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC (Business Wire)
Jun-07-24 08:00AM	UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-06-24 08:00AM	UroGen Pharma to Host UGN-102 Virtual Data Event on June 13, 2024 (Business Wire)
Jun-05-24 08:00AM	UroGen Pharma to Present at the 45th Annual Goldman Sachs Global Healthcare Conference (Business Wire)
Jun-03-24 08:00AM	UroGen Pharma Appoints David Lin as New Chief Commercial Officer (Business Wire)
May-22-24 08:00AM	UroGen Pharma to Present at the TD Cowen 5th Annual Oncology Innovation Summit (Business Wire)
May-14-24 08:20AM	UroGen Pharma Ltd. (NASDAQ:URGN) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-13-24 12:53PM	URGN Stock Earnings: UroGen Pharma Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
09:32AM	UroGen Pharma Ltd (URGN) Q1 2024 Earnings: Misses EPS Estimates, Revenue Slightly Above Expectations (GuruFocus.com)
08:00AM	Loading…
08:00AM	UroGen Pharma Announces Date for ENVISION Data, New Long-Term Jelmyto Durability Data, and Reports 2024 First Quarter Financial Results and Business Highlights (Business Wire)
May-07-24 08:00AM	UroGen Pharma to Participate at Upcoming Investor Conferences (Business Wire)
May-05-24 12:20PM	New Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival (RFS) at 24 Months with JELMYTO Across All Studied Patient and Disease Characteristics in Cohort of Responders to Induction Therapy (Business Wire)
May-04-24 03:20PM	UroGen Announces Results from ATLAS Showing Robust UGN-102 Durability of Response in New and Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer at AUA 2024 (Business Wire)
11:50AM	New Real-World Study on Retrograde Instillation of JELMYTO for Treatment of Low-Grade Upper Tract Urothelial Cancer Reports Similar Complete Response Rate and Lower Stricture Rate Compared to OLYMPUS Pivotal Trial (Business Wire)
May-03-24 08:00AM	UroGen Pharma to Report 2024 First Quarter Financial Results on Monday, May 13, 2024 (Business Wire)
Apr-17-24 12:02PM	UroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial Cancers (Business Wire)
Apr-15-24 08:00AM	UroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (Business Wire)
Apr-03-24 08:00AM	UroGen Pharma Files Patent Infringement Action Against Teva Pharmaceuticals (Business Wire)
Mar-15-24 10:30AM	UroGen Pharma Ltd. (NASDAQ:URGN) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-14-24 12:53PM	URGN Stock Earnings: UroGen Pharma Misses EPS, Beats Revenue for Q4 2023 (InvestorPlace) -17.97%
09:32AM	UroGen Pharma Ltd (URGN) Reports Solid JELMYTO Growth Amidst Financial Challenges (GuruFocus.com)
09:10AM	Urogen Pharma (URGN) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
08:00AM	UroGen Pharma Delivers Double Digit JELMYTO Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102 (Business Wire)
Mar-08-24 08:00AM	UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
08:00AM	Loading…
Mar-04-24 08:00AM	UroGen Pharma to Report Fourth Quarter and Full-Year 2023 Financial Results on Thursday, March 14, 2024 (Business Wire)
Feb-26-24 08:00AM	UroGen Pharma to Present at TD Cowen 44th Annual Health Care Conference (Business Wire) +5.09%
Feb-01-24 08:00AM	UroGen Pharma to Participate at Upcoming Investor Conferences (Business Wire)
Jan-24-24 08:00AM	UroGen Initiates Submission of a Rolling NDA to the FDA for UGN-102 (Business Wire)
Jan-17-24 08:00AM	UroGen Secures Exclusive License from medac GmbH to Develop a Next-Generation Novel Mitomycin-Based Formulation for Urothelial Cancers (Business Wire) +6.27%
Jan-11-24 08:00AM	UroGen Pharma to Participate in the B. Riley Healthcare Conference (Business Wire)
Dec-08-23 04:00PM	UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-15-23 01:50PM	UroGen Pharma Ltd. (NASDAQ:URGN) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-14-23 12:19PM	UroGen Pharma Ltd (URGN) Reports Growth in Q3 Revenue and Progress in Clinical Trials (GuruFocus.com)
08:00AM	UroGen Pharma Reports Third Quarter 2023 Financial Results (Business Wire)
Nov-13-23 08:00AM	UroGen will Present Scientific Advances in Bladder Cancer at the Annual Meeting of the Society of Urologic Oncology (Business Wire)
Nov-07-23 08:00AM	UroGen Pharma to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023 (Business Wire)
Oct-03-23 08:00AM	Following Pre-NDA Meeting with the FDA, UroGen Announces Rolling NDA Submission for UGN-102 to Begin January 2024 (Business Wire)
Sep-11-23 07:00AM	Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors (GlobeNewswire)
Sep-08-23 08:00AM	UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-31-23 08:00AM	UroGen Pharma to Present at Upcoming Investor Conferences (Business Wire)
Aug-18-23 01:40PM	UroGen Pharma (URGN) Stock Surges 89% in a Month: Here's Why (Zacks)
Aug-17-23 07:00AM	New Treatment for Bladder Cancer Offers This Biotech a Second Chance (The Wall Street Journal) -14.16%
Aug-12-23 09:18AM	UroGen Pharma Ltd. (NASDAQ:URGN) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-10-23 09:55AM	Wall Street Analysts Think Urogen Pharma (URGN) Could Surge 89.61%: Read This Before Placing a Bet (Zacks)
09:15AM	Urogen Pharma (URGN) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
08:00AM	UroGen Pharma Reports Record JELMYTO Quarterly Sales and Recent Corporate Developments (Business Wire)
Aug-08-23 08:00AM	The Journal of Urology Publishes Peer-Reviewed Article Highlighting UGN-102 Data in Non-Surgical Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (Business Wire)
Aug-02-23 05:00PM	UroGen Pharma to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023 (Business Wire) -6.45%
Aug-01-23 10:05AM	Opportunities Outweigh Risks: Oppenheimer Sees at Least 60% Gains in These 2 Stocks (TipRanks) -6.28%
Jul-31-23 08:00AM	UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-28-23 01:41PM	Why Shares of UroGen Pharma Jumped Friday (Motley Fool) +26.38%
Jul-27-23 09:55AM	UroGen Announces $120 Million Private Placement of Ordinary Shares (Business Wire) +98.56%
09:50AM	UGN-102, in Development as the Potential First Non-Surgical Therapy for LG-IR-NMIBC, Met Primary Endpoints in Both Phase 3 ATLAS and ENVISION Clinical Trials (Business Wire)
Jul-25-23 04:10PM	UroGen Pharma Announces the Appointment of James Robinson to its Board of Directors (Business Wire)
Jul-10-23 08:00AM	Retrospective Study Finds JELMYTO® Use Effective Following Partial Ablation or Biopsy in Larger Volume Low-Grade Upper Tract Urothelial Tumors that Impede Kidney Preservation (Business Wire) -5.28%
Jul-06-23 08:00AM	UroGen Pharma to Host UGN-102 Data Event on July 27, 2023 (Business Wire) +5.08%
Jun-20-23 08:00AM	Retrospective Study Reveals Lower Stricture Rate and Comparable Oncological Outcomes with Antegrade Administration of JELMYTO® Versus Retrograde Administration (Business Wire)
Jun-09-23 08:00AM	UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +5.33%
Jun-02-23 08:00AM	UroGen Pharma to Present at Upcoming Investor Conferences (Business Wire)
May-22-23 01:18PM	With 58% institutional ownership, UroGen Pharma Ltd. (NASDAQ:URGN) is a favorite amongst the big guns (Simply Wall St.)
May-16-23 12:13PM	UroGen Pharma Ltd. (NASDAQ:URGN) Q1 2023 Earnings Call Transcript (Insider Monkey)
May-11-23 09:15AM	Urogen Pharma (URGN) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +8.00%
08:00AM	UroGen Pharma Meets Revenue Goal, Reports First Quarter 2023 Financial Results and Recent Corporate Developments (Business Wire)
May-04-23 08:00AM	UroGen Pharma to Report 2023 First Quarter Financial Results on Thursday, May 11, 2023 (Business Wire)
May-02-23 10:02AM	Earnings Preview: Urogen Pharma (URGN) Q1 Earnings Expected to Decline (Zacks) -8.61%
May-01-23 02:00PM	First Study to Evaluate JELMYTO® Use Post-Complete Endoscopic Ablation Reports 69% of Patients were Disease Free at the Time of First Endoscopic Evaluation (Business Wire) +23.30%
Apr-30-23 08:00AM	New Retrospective Study Presented at AUA 2023 Provides Evidence of Similar Outcomes Utilizing JELMYTO® in the Treatment of UTUC of the Ureter and Renal Pelvis (Business Wire)
Apr-25-23 08:00AM	UroGen Pharma to Present at H.C. Wainwright BioConnect Conference (Business Wire)
Apr-18-23 12:16PM	UroGen Pharma Ltd.'s (NASDAQ:URGN) Prospects Need A Boost To Lift Shares (Simply Wall St.)
Mar-18-23 02:06AM	UroGen Pharma Ltd. (NASDAQ:URGN) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-16-23 09:15AM	Urogen Pharma (URGN) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
08:00AM	UroGen Pharma Reports Highest Revenue Quarter and Significant Full Year 2022 Growth and Recent Corporate Developments (Business Wire)
Mar-09-23 04:00PM	UroGen Pharma to Report Fourth Quarter and Full-Year 2022 Financial Results on Thursday, March 16, 2023 (Business Wire) -8.27%
Mar-06-23 08:00AM	UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-01-23 04:00PM	UroGen Pharma to Present at Upcoming Investor Conferences (Business Wire)
Feb-27-23 08:15AM	Axsome Therapeutics (AXSM) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
Feb-15-23 09:06AM	Investigational Therapy UGN-102 May Be Delivered at Home for the Treatment of Bladder Cancer (Business Wire)
Feb-06-23 05:33AM	UroGen Pharma Ltd. (NASDAQ:URGN) Is Expected To Breakeven In The Near Future (Simply Wall St.)
Jan-11-23 08:00AM	Results of the First Post-Commercial Utilization Review of JELMYTO® Provide New Evidence that Reinforces its Efficacy and Safety in Patients with Low-Grade Upper Tract Urothelial Cancer (Business Wire)
Jan-09-23 12:19PM	The past five years for UroGen Pharma (NASDAQ:URGN) investors has not been profitable (Simply Wall St.)
Dec-19-22 08:00AM	UroGen Completes Enrollment of Its Phase 3 Clinical Trial for UGN-102 in Development for Low-Grade, Intermediate-Risk, Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC) (Business Wire)
Dec-13-22 12:13PM	With 57% institutional ownership, UroGen Pharma Ltd. (NASDAQ:URGN) is a favorite amongst the big guns (Simply Wall St.)
Dec-09-22 08:00AM	UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-02-22 12:00PM	UroGen Announces New Data from the OPTIMA II Study that Show Median Durability of Response of 24.4 Months for UGN-102, an Investigational Non-Surgical Chemoablative Treatment for Low-Grade, Intermediate-Risk Non-Muscle Invasive Bladder Cancer (Business Wire)
Dec-01-22 07:00PM	UroGen Announces New Data from the OLYMPUS Trial that Shows Median Durability of Response of 28.9 Months for JELMYTO®, the Only Non-Surgical, Chemoablative Treatment for Adults with Low-Grade Upper Tract Urothelial Cancer (Business Wire)
Nov-21-22 04:00PM	UroGen Pharma to Present at Evercore ISI 5th Annual Virtual HealthCONx Conference (Business Wire) -7.51%
Nov-16-22 11:24AM	Some Analysts Just Cut Their UroGen Pharma Ltd. (NASDAQ:URGN) Estimates (Simply Wall St.)
Nov-14-22 08:00AM	UroGen Highlights New Real-World Safety Data Published in The British Journal of Urology International That Showed a Low Rate of Ureteral Stenosis When Antegrade Administration of JELMYTO® was Used in Patients with Upper Tract Urothelial Carcinoma (Business Wire)
Nov-12-22 07:33AM	UroGen Pharma Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag (Simply Wall St.)
Nov-10-22 09:15AM	Urogen Pharma (URGN) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -16.32%
08:00AM	UroGen Pharma Reports Third Quarter 2022 Financial Results and Recent Corporate Developments (Business Wire)
Nov-09-22 08:00AM	UroGen Announces the Appointment of Dan Wildman to the UroGen Pharma Board of Directors (Business Wire) -7.66%
Nov-03-22 08:00AM	UroGen Pharma to Report Third Quarter 2022 Financial Results on Thursday, November 10, 2022 (Business Wire)
Oct-12-22 04:29AM	Urogen Pharma (URGN) Moves 10.3% Higher: Will This Strength Last? (Zacks) +6.22%

UroGen Pharma Ltd. is a biopharmaceutical company, which engages in developing and commercializing innovative solutions that treat urothelial and specialty cancers. It also focuses on developing RTGel reverse-thermal hydrogel, a proprietary sustained release and hydrogel-based platform technology. The company was founded by Asher Holzer in 2004 and is headquartered in Princeton, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Schoenberg Mark	Chief Medical Officer	Jun 10 '24	Sale	13.08	5,153	67,401	144,284	Jun 11 01:15 PM
Schoenberg Mark	Chief Medical Officer	Mar 18 '24	Sale	14.05	12,000	168,600	139,437	Mar 20 04:38 PM
Smith Jason Drew	General Counsel	Jan 31 '24	Sale	15.74	4,993	78,590	18,824	Feb 02 07:12 PM
Schoenberg Mark	Chief Medical Officer	Jan 31 '24	Sale	15.74	3,789	59,639	149,423	Feb 02 07:07 PM
Smith Jason Drew	General Counsel	Aug 31 '23	Sale	18.01	3,800	68,438	18,407	Sep 05 04:28 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

URGN

UroGen Pharma Ltd

Upgrade your FINVIZ experience